AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03091309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive educational video
Description: A web-link to an educational video on IBD and pregnancy tailored to emphasize the importance of optimal disease control and medication adherence.
Study NCT03091309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Initial in-person counseling with an IBD nurse
Description: This session will emphasize key points from the educational video and the nurse will answer any additional questions the subject may have. The nurse will assess subjects' medication adherence and specifically query any concerns subjects may have regarding specific medications and discuss their intentions to be adherent throughout pregnancy.
Study NCT03091309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: The nurse will be trained in a technique known as motivational interviewing (MI) specifically adapted for optimizing medication adherence during pregnancy.
Study NCT03091309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine-based follow-up
Description: The IBD nurse will arrange follow-up visits with each subject on a monthly basis with additional ad-hoc sessions as needed. The encounter will focus on monitoring disease activity adherence and applying MI communication skills to reinforce and improve the latter.
Study NCT03091309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monthly follow-up questionnaires
Description: Web-based short questionnaires, administered monthly, will be used to assess medication adherence \[self-reported using the 5 item Medication Adherence Report Scale (MARS-5)\] and IBD related disease activated \[self-reported using PRO-2 scale for Crohn's Disease related disease activity and 6-Point Mayo Score for Ulcerative Colitis related disease activity\].
Study NCT03091309 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive questionnaires
Description: Web-based detailed questionnaires, administered at enrolment and gestational week 34, will be used to assess medication adherence \[self-reported using the Medication Adherence Report Scale (MARS-5)\], patient trust in physician \[self-reported using the Trust in Physician Scale (TIPS)\], IBD related disease activated \[self-reported using the PRO-2 or 6-Point Mayo Score\], IBD-specific health related quality of life \[self-reported using the Inflammatory Bowel Disease Questionnaire (IBDQ)\], patient satisfaction \[self-reported using the Patient Satisfaction with Healthcare in Inflammatory Bowel Disease (CACHE) questionnaire\]and IBD specific knowledge \[self-reported using the Crohn's and Colitis Knowledge (CCKNOW) questionnaire\].
Study NCT03091309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive questionnaires
Description: Web-based detailed questionnaires, administered at enrolment and gestational week 34, will be used to assess medication adherence \[self-reported using the Medication Adherence Report Scale (MARS-5)\], patient trust in physician \[self-reported using the Trust in Physician Scale (TIPS)\], IBD related disease activated \[self-reported using the PRO-2 or 6-Point Mayo Score\], IBD-specific health related quality of life \[self-reported using the Inflammatory Bowel Disease Questionnaire (IBDQ)\], patient satisfaction \[self-reported using the Patient Satisfaction with Healthcare in Inflammatory Bowel Disease (CACHE) questionnaire\]and IBD specific knowledge \[self-reported using the Crohn's and Colitis Knowledge (CCKNOW) questionnaire\].
Study NCT01596998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine with epinephrine
Description: The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz Sonosite M-Turbo®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% with 5 µg/mL epinephrine were injected.
Study NCT01596998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine without epinephrine
Description: The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz, Sonosite M-Turbo ®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% were injected.
Study NCT01596998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring
Description: Standard anesthetic monitoring was used, including continuous electrocardiogram, non invasive blood pressure and peripheral oxygen saturation. Later, under local anesthesia a permeable venous line and an arterial line were installed for blood sampling measures to determine local anesthetic plasma levels.
Study NCT01596998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring
Description: Standard anesthetic monitoring was used, including continuous electrocardiogram, non invasive blood pressure and peripheral oxygen saturation. Later, under local anesthesia a permeable venous line and an arterial line were installed for blood sampling measures to determine local anesthetic plasma levels.
Study NCT01596998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Determining the extent of the block
Description: The extent of sensory block was measured by assessment of temperature, soft and hard touch using alcohol, cotton and pin prick respectively. These measurements were made every 10 minutes during the first hour and every 30 minutes to complete 4 hours.
Study NCT03759535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Acute rejection
Description: Donor derived cell free DNA
Study NCT00921700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen + Paracetamol
Description: Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg in gelatine capsules
Study NCT00921700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen + Paracetamol + Codeine
Description: Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg and codeine 60 mg in gelatine capsules
Study NCT00921700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol + Codeine
Description: Single oral dose of paracetamol (acetaminophen) 1000 mg combined with codeine 60 mg in gelatine capsules
Study NCT00921700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of lactose as placebo in gelatine capsules
Study NCT03726164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Conditioning
Description: A Blood pressure cuff will be placed on the arm and inflated to 200mm hg for 5 minutes, and then deflated for 5 minutes, a cycle repeated 3 times.
Study NCT03726164 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham protocol
Description: An un-inflated blood pressure cuff will be placed on the arm for 20 minutes.
Study NCT00836212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reducing dose of Lopinavir
Description: Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
Study NCT00836212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reducing dose of efavirenz
Description: Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
Study NCT01791192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720
Description: Fingolimod
Study NCT01791192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Corticosteroid
Description: Oral Corticosteroid
Study NCT02519166 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 1 clinical examination of the wound, 1 sample taken with the curette, 1 sample by swabbing
Study NCT04421495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: the eligible patients will be give damanid-containing regimen
Study NCT04159038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The immediate intervention group will receive training on how to identify children at risk for developmental disabilities and how to refer to Early Intervention/Early Childhood Special Education.
Study NCT04159038 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The control group will continue usual WIC care.
Study NCT01141595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapropterin dihydrochloride
Description: Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
Study NCT03150225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent training
Description: In this protocol the participants will perform aerobic and resistance training according to published evidence for middle-aged men; Characterized as concurrent training.~The protocol will last six months and will be divided into two quarters. In the first trimester, initial 30 minutes will be assigned to resistance training, followed by 30 minutes of aerobic training; Already in the second trimester will be 20 initial minutes for the aerobic training and later 40 minutes for the resistance training; Aiming to obtain benefits in the levels of muscular strength, aerobic capacity, body composition, besides positive results in relation to the hormonal adaptations of testosterone, as well as in the psychological well being of the participants. Classes will occur at a frequency of three times weekly, lasting 60 minutes a session.
Study NCT03150225 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eurycoma longifolia
Description: Eurycoma longifolia will be administered by supplementation with the standard aqueous-soluble extract extract (Physta ™) in single 200mg capsules daily, and placebo by starch capsules. The supplementatio will last six months.
Study NCT03150225 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eurycoma longifolia
Description: Eurycoma longifolia will be administered by supplementation with the standard aqueous-soluble extract extract (Physta ™) in single 200mg capsules daily, and placebo by starch capsules. The supplementatio will last six months.
Study NCT02689830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bead Block
Description: Prostate embolization
Study NCT00516737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: rizatriptan benzoate
Description: Rizatriptan 10 mg Orally Disintegrating Tablet (ODT); one dose, treatment of a single migraine attack
Study NCT00516737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Matching placebo; one dose, treatment of a single migraine attack
Study NCT03911765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital cognitive training
Description: Digital cognitive exercises, used in the intervention group, have the primary objective of stimulating executive functions, and will be made available through the Internet using the BrainHQ platform.
Study NCT03911765 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: digital cognitive training
Description: Digital cognitive exercises, used in the intervention group, have the primary objective of stimulating executive functions, and will be made available through the Internet using the BrainHQ platform.
Study NCT00870753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 90 min hatha yoga 2 times per week for 12 weeks.
Study NCT01357369 — intervention group
Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: Blood samples will be drawn from the mother, umbilical vein and artery post delivery, and neonate with other clinical labs.
Study NCT02122978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Cognitive Therapy
Description: MBCT 8 week course delivered by trained facilitator
Study NCT02122978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBSC - minimal contact
Description: 8 week course in Mindfulness Based Self Compassion delivered remotely by audio guided MP3
Study NCT02122978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Self Compassion Therapy
Description: Mindfulness Based Self Compassion Therapy - 8 wee course delivered by trained facilitator
Study NCT03790280 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HFO analysis
Description: We hypothesize that the strategy of incorporating HFO data to a standard ECoG-guided resection in pediatric epilepsy surgery will result in improved postoperative seizure outcome than the traditional approach.
Study NCT01049763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir
Description: oseltamivir 150 mg single oral dose oseltamivir 75 mg single oral dose
Study NCT01049763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir
Description: oseltamivir 150 mg single oral dose oseltamivir 75 mg single oral dose
Study NCT01446419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracept Treatment
Description: Percutaneous transpedicular RF ablation of an intraosseous nerve within the lumbar vertebral body to treat chronic axial low back.
Study NCT01446419 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Percutaneous transpedicular access to the lumbar vertebra, no RF ablation delivered.
Study NCT01767883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitated Clinical Decision Support
Description: The primary care practices in this arm will receive:~* CKD decision support algorithms added to their Clinical Decision Support~* System Academic detailing concerning the rationale for the algorithms~* On-going mentoring and practice facilitation~* Audit and feedback during quarterly reviews of practice data with the practice facilitator by videoconference.
Study NCT01767883 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Decision Support Only
Description: * CKD decision support algorithms added to their Clinical Decision Support~* System Academic detailing concerning the rationale for the algorithms
Study NCT00915343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone (modified release), oral tablet 20 and 5 mg
Description: The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state. The dose was the same as patients have had before entering the trial
Study NCT00915343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone, oral tablet, 10 mg
Description: The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM). The morning dose was administered in the fasting state. The total daily dose was the same as in the experimental treatment arm.
Study NCT02349698 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Chimeric Antigen Receptor Modified T cells Targeting CD19
Description: T cells modified with CD19 targeted chimeric antigen receptor.
Study NCT03286855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Mesh Nebuliser
Description: The Aerogen Ultra vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.
Study NCT03286855 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Hospital Care
Description: The standard hospital care refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications. This is the Hudson micromist small volume nebuliser.
Study NCT03186235 — intervention group
Intervention type: OTHER
Intervention: Flow cytometry
Description: Isolation of T regulatory cells from blood
Study NCT01233778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Canola Oil
Description: 60g Canola oil daily per 3000kcal diet provided in a supplemental shake
Study NCT01233778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Oleic Acid + DHA Canola Oil
Description: 60g high oleic acid canola oil + DHA daily per 3000kcal provided in a supplemental shake
Study NCT01233778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Oleic Acid Canola Oil
Description: 60g high oleic acid canola oil daily per 3000kcal provided in a supplemental shake
Study NCT01233778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flax Oil
Description: 36g flax oil + 24g safflower oil daily per 3000kcal provided in a supplemental shake
Study NCT01233778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Safflower Oil
Description: 45g safflower oil + 15g corn oil daily per 3000kcal provided in a supplemental shake
Study NCT01928160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV
Study NCT01928160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT01928160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT01928160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT01928160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04884555 — intervention group
Intervention type: OTHER
Intervention: Standard neurorehabilitation
Description: Routine post-stroke rehabilitation
Study NCT04884555 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thiol-Disulphide Homeostasis
Description: Monitoring the levels of thiol and disulphide in serum
Study NCT04884555 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oxidized-reduced Glutathione Homeostasis
Description: Monitoring the levels of intracellular oxidized glutathione and reduced glutathione in whole blood samples
Study NCT00987363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraarterial infusion of autologous bone marrow cells
Description: Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x10 E8, 5x10E8 and 1x10 E9 in the low,intermediate and high dose arms respectively
Study NCT01708460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin.
Study NCT02849366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance
Study NCT02849366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance
Study NCT02849366 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
Study NCT04442841 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Description: It may be GSk or MSD vaccine
Study NCT03721926 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants assigned to receive usual oncology care will not meet with the study nurses, though they may receive geriatric or palliative care consults at their request or at the discretion of their treating oncologist.
Study NCT03721926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric Oncology Collaborative Care
Description: Patients receive three visits with a trained study nurse. At each visit, the study nurse will assess the patient's symptom burden, functional status, comorbid conditions, psychosocial issues, and medication use. The nurses can refer patients to specialists as needed. The study nurses will meet with a supervising support team, consisting of clinicians from geriatrics, palliative care, social work, and pharmacy to discuss each patient and review documentation. Following the team meetings, the nurses will document recommendations in the medical record and communicate with the primary oncology team, either in person or via phone, as appropriate. The study nurses will contact the supervising team in between meetings for any urgent issues or questions that arise.
Study NCT00679705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritodrine
Description: Ritodrine (Pre-Par), maximum 400 µg/minute, IV
Study NCT00679705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atosiban
Description: Atosiban (Tractocile), maximum 300 µg/minute, IV
Study NCT00679705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glucose 5%, IV
Study NCT02847130 — intervention group
Intervention type: OTHER
Intervention: Informational Intervention
Description: Participate in focus group